Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
In 2006 was created Qiming Venture Partners, which is appeared as VC. The main office of represented VC is situated in the Shanghai. The fund was located in Asia if to be more exact in China.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Internet, Biotechnology. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Xiaomi, Meituan-Dianping, ChinaCache. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
When the investment is from Qiming Venture Partners the average startup value is more than 1 billion dollars. Opposing the other organizations, this Qiming Venture Partners works on 21 percentage points less the average amount of lead investments. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2018. The fund is generally included in 25-48 deals every year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Besides them, we counted 12 critical employees of this fund in our database.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Qiming Venture Partners, startups are often financed by K2VC, China Growth Capital, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are TF Capital, Northern Light Venture Capital, Kleiner Perkins. In the next rounds fund is usually obtained by Matrix Partners China, Goldman Sachs, GGV Capital.
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Supervision Technology | 07 Sep 2022 | Guangzhou, Guangdong, China | |||
Prismlab China Ltd | $30M | 26 Aug 2022 | Minhang District, China | ||
DeepWay | $71M | 23 Aug 2022 | Beijing, Beijing, China | ||
Insilico Medicine | $35M | 10 Aug 2022 | Hong Kong Island, Hong Kong, China | ||
Oricell Therapeutics | $120M | 01 Aug 2022 | Shanghai, Shanghai, China | ||
Chatail | $10M | 22 Jul 2022 | Shanghai, China | ||
This Core Technology | 19 Jul 2022 | Shanghai, Shanghai, China | |||
Gaugene | $15M | 15 Jul 2022 | Dongcheng District, Beijing, China | ||
Ark Biosciences | 14 Jul 2022 | Shanghai, China |
– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
